Cargando…

Safety, anti-tumour activity, and pharmacokinetics of fixed-dose SHR-1210, an anti-PD-1 antibody in advanced solid tumours: a dose-escalation, phase 1 study

BACKGROUND: To assess the safety profile, pharmacokinetics, pharmacodynamics and preliminary antitumour activity of fixed-dose SHR-1210, a novel anti-PD-1 antibody, in advanced solid tumours. METHODS: A total of 36 patients with advanced solid tumours received intravenous SHR-1210 at 60 mg, 200 mg a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mo, Hongnan, Huang, Jing, Xu, Jiachen, Chen, Xuelian, Wu, Dawei, Qu, Dong, Wang, Xi, Lan, Bo, Wang, Xingyuan, Xu, Jianping, Zhang, Honggang, Chi, Yihebali, Yang, Qing, Xu, Binghe
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2018
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6162236/ https://www.ncbi.nlm.nih.gov/pubmed/29755117 http://dx.doi.org/10.1038/s41416-018-0100-3

Ejemplares similares

Reactive capillary hemangiomas: a novel dermatologic toxicity following anti-PD-1 treatment with SHR-1210
por: Chen, Xuelian, et al.
Publicado: (2019)

Lactate dehydrogenase and baseline markers associated with clinical outcomes of advanced esophageal squamous cell carcinoma patients treated with camrelizumab (SHR‐1210), a novel anti‐PD‐1 antibody
por: Wang, Xi, et al.
Publicado: (2019)

Anti-PD1 ‘SHR-1210ʹ aberrantly targets pro-angiogenic receptors and this polyspecificity can be ablated by paratope refinement
por: Finlay, William J.J., et al.
Publicado: (2018)

Efficacy of anti-PD-1 antibody SHR-1210 as second-line treatment in hepatocellular carcinoma patient with sorafenib resistance: A case report
por: Zhu, Hong, et al.
Publicado: (2019)

Bifunctional anti-PD-L1/TGF-βRII agent SHR-1701 in advanced solid tumors: a dose-escalation, dose-expansion, and clinical-expansion phase 1 trial
por: Liu, Dan, et al.
Publicado: (2022)

Safety, tolerability, and pharmacokinetics of an anti-LAG-3 antibody SHR-1802 in patients with advanced solid tumors: a phase I dose-escalation and dose-expansion study
por: Deng, Ting, et al.
Publicado: (2023)

A dose-escalating phase I of imatinib mesylate with fixed dose of metronomic cyclophosphamide in targeted olid tumours
por: Adenis, A, et al.
Publicado: (2013)

Apatinib plus camrelizumab (anti-PD1 therapy, SHR-1210) for advanced osteosarcoma (APFAO) progressing after chemotherapy: a single-arm, open-label, phase 2 trial
por: Xie, Lu, et al.
Publicado: (2020)

Phase I dose-escalation and expansion study of PARP inhibitor, fluzoparib (SHR3162), in patients with advanced solid tumors
por: Li, Huiping, et al.
Publicado: (2020)

First-in-human, dose-escalation, phase 1 study of anti-angiopoietin-2 LY3127804 as monotherapy and in combination with ramucirumab in patients with advanced solid tumours
por: Martin-Liberal, Juan, et al.
Publicado: (2020)

A phase 1 dose-escalation study of veliparib with bimonthly FOLFIRI in patients with advanced solid tumours
por: Berlin, Jordan, et al.
Publicado: (2018)

Active immunotherapy of L1210 leukaemia applied after the graft of tumour cells.
por: Mathé, G., et al.
Publicado: (1969)

Multiple doses of SHR-1222, a sclerostin monoclonal antibody, in postmenopausal women with osteoporosis: A randomized, double-blind, placebo-controlled, dose-escalation phase 1 trial
por: Dai, Zhijie, et al.
Publicado: (2023)

Correction: Apatinib plus camrelizumab (anti-PD1 therapy, SHR-1210) for advanced osteosarcoma (APFAO) progressing after chemotherapy: a single-arm, open-label, phase 2 trial
Publicado: (2020)

A dose-escalation study of indisulam in combination with capecitabine (Xeloda) in patients with solid tumours
por: Siegel-Lakhai, W S, et al.
Publicado: (2008)

Bosutinib plus capecitabine for selected advanced solid tumours: results of a phase 1 dose-escalation study
por: Isakoff, S J, et al.
Publicado: (2014)

Maximum Tolerated Dose and Pharmacokinetics of Paclitaxel Micellar in Patients with Recurrent Malignant Solid Tumours: A Dose-Escalation Study
por: Borgå, Olof, et al.
Publicado: (2019)

A phase I clinical trial of dose escalation of lobaplatin in combination with fixed-dose docetaxel for the treatment of human solid tumours that had progressed following chemotherapy
por: PENG, YU, et al.
Publicado: (2015)

Do selective radiation dose escalation and tumour hypoxia status impact the loco-regional tumour control after radio-chemotherapy of head & neck tumours? The ESCALOX protocol
por: Pigorsch, Steffi U., et al.
Publicado: (2017)

The influence of the schedule and the dose of gemcitabine on the anti-tumour efficacy in experimental human cancer.
por: Boven, E., et al.
Publicado: (1993)

Assessment and impact of dose escalation on anti-drug antibodies in Fabry disease
por: Lenders, Malte, et al.
Publicado: (2022)

A phase 1, open-label, dose-escalation trial of oral TSR-011 in patients with advanced solid tumours and lymphomas
por: Lin, Chia-Chi, et al.
Publicado: (2019)

Phase I dose escalation study of telatinib (BAY 57-9352) in patients with advanced solid tumours
por: Strumberg, D, et al.
Publicado: (2008)

Phase I dose-escalation study of aflibercept in combination with docetaxel and cisplatin in patients with advanced solid tumours
por: Freyer, G, et al.
Publicado: (2012)

The effect of dose escalation on gastric toxicity when treating lower oesophageal tumours: a radiobiological investigation
por: Carrington, Rhys, et al.
Publicado: (2015)

Efficacy of irinotecan-based chemotherapy after exposure to an anti-PD-1 antibody in patients with advanced esophageal squamous cell carcinoma
por: Zhang, Bo, et al.
Publicado: (2019)

Oral reactive capillary hemangiomas induced by SHR-1210 in the treatment of non-small cell lung cancer: a case report and literature review
por: Zhou, Jinhan, et al.
Publicado: (2021)

Dose escalation study of an anti-thrombocytopenic agent in patients with chemotherapy induced thrombocytopenia
por: Levin, Robert D, et al.
Publicado: (2010)

Phase I study of dose-escalated paclitaxel, ifosfamide, and cisplatin (PIC) combination chemotherapy in advanced solid tumours
por: Kosmas, C, et al.
Publicado: (2000)

Radiation dose for thymic tumours
por: Lalani, Nafisha, et al.
Publicado: (2020)

Pharmacology of liposomal vincristine in mice bearing L1210 ascitic and B16/BL6 solid tumours.
por: Mayer, L. D., et al.
Publicado: (1995)

A dose escalation and pharmacokinetic study of biweekly pegylated liposomal doxorubicin, paclitaxel and gemcitabine in patients with advanced solid tumours
por: Bozionelou, V, et al.
Publicado: (2007)

Baseline tumour necrosis factor alpha levels predict the necessity for dose escalation of infliximab therapy in patients with rheumatoid arthritis
por: Takeuchi, Tsutomu, et al.
Publicado: (2011)

A phase I dose-escalation study of aflibercept administered in combination with pemetrexed and cisplatin in patients with advanced solid tumours
por: Diaz-Padilla, I, et al.
Publicado: (2012)

Larotrectinib in adult patients with solid tumours: a multi-centre, open-label, phase I dose-escalation study
por: Hong, D S, et al.
Publicado: (2019)

The safety, tolerability and pharmacokinetics of niraparib in Japanese patients with solid tumours: results of a phase I dose-escalation study
por: Yonemori, Kan, et al.
Publicado: (2021)

Escalating a Biological Dose of Radiation in the Target Volume Applying Stereotactic Radiosurgery in Patients with Head and Neck Region Tumours
por: Polanowski, Paweł, et al.
Publicado: (2022)

Phase 1A/1B dose-escalation and -expansion study to evaluate the safety, pharmacokinetics, food effects and antitumor activity of pamiparib in advanced solid tumours
por: Lickliter, Jason D., et al.
Publicado: (2021)

Avelumab in paediatric patients with refractory or relapsed solid tumours: dose-escalation results from an open-label, single-arm, phase 1/2 trial
por: Loeb, David M., et al.
Publicado: (2022)

Single Dose of SHR-1222, a Sclerostin Monoclonal Antibody, in Healthy Men and Postmenopausal Women With Low Bone Mass: A Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation, Phase I Study
por: Dai, Zhijie, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_524ssppdi60f6g63t8oq97mq23